SCINTIX® biology-guided radiotherapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our X1 platform uses to manage motion and treat solid tumors of any stage disease.
Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Treating cancer isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.
Discover SCINTIX therapy.
See how SCINTIX therapy can play a role
in your cancer program.
Beverly Hills Cancer Center expands patient treatment options in Southern California Hayward, Calif., Oct. 9, 2025 — RefleXion, an external-beam, theranostic oncology company, today announced that Beverly Hills Cancer Center, a leading private cancer diagnostic and treatment facility, has treated its first patient with the RefleXion® X1 dual-treatment modality radiotherapy platform. This milestone marks an […]
When Susanne Kluh learned about SCINTIX therapy from RefleXion, she was uniquely qualified to appreciate the opportunity before her. THE ONCOLOGIST’S ASSESSMENT of her cancer was dire, but Susanne Kluh wasn’t about to let him have the final word. “He said, ‘We can’t treat it. Maybe we could do chemotherapy, but wouldn’t you rather have […]
Let us tell you more.
Contact UsStay up to date.
Sign Up